用免疫内型定义脓毒症与非脓毒症危重患者的危重症:一项队列研究
该研究分析了两个单中心前瞻性观察队列中522例外科ICU患者,入ICU时及设定间隔用nCounter FLEX平台检测29-mRNA转录组分类器(IMX-SEV-3,评估30天死亡可能性)和33-mRNA内型分类器。脓毒症患者预测及实际住院死亡率显著更高;入组时脓毒症与非脓毒症患者均以适应性内型为主但分布显著不同;炎症型及凝血型脓毒症患者、炎症型非脓毒症患者继发感染频率显著更高(p<0.01);57.5%患者ICU住院期间内型发生变化,持续适应性内型预后较好,持续炎症型或凝血型预后较差。脓毒症且预测死亡可能性高的患者中炎症型占49.6%,累积不良结局率67.4%;低死亡风险者无论是否脓毒症几乎均为适应性内型(分别为100%和93.4%)。作者认为未来研究将阐明内型分型能否识别靶向治疗个体。
要点
- 522例外科ICU患者中,入组时脓毒症与非脓毒症均以适应性内型为主,但两者分布显著不同。
- 炎症型及凝血型脓毒症患者、炎症型非脓毒症患者继发感染频率显著高于适应性内型者(p<0.01)。
- 57.5%患者ICU住院期间内型发生改变;持续适应性内型总体预后较好,持续炎症型或凝血型总体结局较差。
- 脓毒症且预测死亡可能性高的患者中炎症型占49.6%,累积不良结局率67.4%。
- 低死亡风险患者无论是否脓毒症几乎均为适应性内型(分别为100%和93.4%)。
适用人群与场景
- 两个单中心前瞻性观察队列中522例外科ICU患者,入ICU时间跨度为截至2020年7月的5年期间。
- 包括脓毒症患者和非脓毒症但仍危重的患者。
诊断标准与关键阈值
- 使用FDA批准的nCounter FLEX®(NanoString, Inc.)分析平台检测29-mRNA转录组分类器(IMX-SEV-3,评估30天死亡可能性)和33-mRNA转录组内型分类器。
- 内型分类包括适应性、炎症型和凝血型。
研究设计与关键结果
- 研究类型:两个单中心前瞻性观察队列分析,共522例外科ICU患者,研究期5年,截至2020年7月。
- 脓毒症与显著更高的预测和实际住院死亡率相关。
- 入组时脓毒症和非脓毒症患者的主要内型均为适应性,但分布显著不同。
- 炎症型和凝血型脓毒症患者以及炎症型非脓毒症患者继发感染频率显著高于适应性内型者(p<0.01)。
- 57.5%的患者在ICU住院期间内型发生变化;持续适应性内型者总体预后较好,持续炎症型或凝血型者总体结局较差。
- 脓毒症且预测死亡可能性高的患者中,炎症型内型占49.6%,累积不良结局率为67.4%。
- 低死亡风险患者中,脓毒症者100%为适应性内型,非脓毒症者93.4%为适应性内型。
- 临床结局包括全因死亡率、慢性危重症的发生和继发感染;进行了单因素和多因素分析以评估真实效应和混杂因素。
证据类型、等级与局限
- 证据类型:两个单中心前瞻性观察队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来研究将阐明对危重脓毒症患者进行内型分型能否识别出适合靶向治疗干预的个体,以改善患者管理和结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis is a heterogenous syndrome with limited therapeutic options. Identifying immunological endotypes through gene expression patterns in septic patients may lead to targeted interventions. We investigated whether patients admitted to a surgical intensive care unit (ICU) with sepsis and with high risk of mortality express similar endotypes to non-septic, but still critically ill patients using two multiplex transcriptomic metrics obtained both on admission to a surgical ICU and at set intervals.
METHODS: We analyzed transcriptomic data from 522 patients in two single-site, prospective, observational cohorts admitted to surgical ICUs over a 5-year period ending in July 2020. Using an FDA-cleared analytical platform (nCounter FLEX®, NanoString, Inc.), we assessed a previously validated 29-messenger RNA transcriptomic classifier for likelihood of 30-day mortality (IMX-SEV-3) and a 33-messenger RNA transcriptomic endotype classifier. Clinical outcomes included all-cause mortality, development of chronic critical illness, and secondary infections. Univariate and multivariate analyses were performed to assess for true effect and confounding.
RESULTS: Sepsis was associated with a significantly higher predicted and actual hospital mortality. At enrollment, the predominant endotype for both septic and non-septic patients was adaptive, though with significantly different distributions. Inflammopathic and coagulopathic septic patients, as well as inflammopathic non-septic patients, showed significantly higher frequencies of secondary infections compared to those with adaptive endotypes (p < 0.01). Endotypes changed during ICU hospitalization in 57.5% of patients. Patients who remained adaptive had overall better prognosis, while those who remained inflammopathic or coagulopathic had worse overall outcomes. For severity metrics, patients admitted with sepsis and a high predicted likelihood of mortality showed an inflammopathic (49.6%) endotype and had higher rates of cumulative adverse outcomes (67.4%). Patients at low mortality risk, whether septic or non-septic, almost uniformly presented with an adaptive endotype (100% and 93.4%, respectively).
CONCLUSION: Critically ill surgical patients express different and evolving immunological endotypes depending upon both their sepsis status and severity of their clinical course. Future studies will elucidate whether endotyping critically ill, septic patients can identify individuals for targeted therapeutic interventions to improve patient management and outcomes.
参考来源
- Balch JA, Chen UI, Liesenfeld O, et al. Defining critical illness using immunological endotypes in patients with and without sepsis: a cohort study. Crit Care. 2023. PMID: 37474944. doi:10.1186/s13054-023-04571-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。